A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib
Status:
NOT_YET_RECRUITING
Trial end date:
2029-07-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label phase 2 study that will enroll KRASG12C mutated patients with locally advanced or metastatic NSCLC, receiving treatment (ABSK043 in combination with Glecirasib) in a 21-day combination cycle.